Cancer prevention: The importance of accurate risk assessment

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 6, 2005, Pages 1357-1358

  Brown, Powel H ^a   Rashid, Asma ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; PROTEIN RET; RALOXIFENE; RETINOID DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BLEEDING; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GENETIC RISK; HEAD AND NECK CANCER; HIGH RISK POPULATION; HUMAN; MASTECTOMY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SMOKING CESSATION; STROKE; THROMBOEMBOLISM; THYROID CANCER; UTERUS CANCER; VITAMIN SUPPLEMENTATION;

BREAST NEOPLASMS; HUMANS; NEOPLASMS; PREVENTIVE MEDICINE; RISK ASSESSMENT;

EID: 20444422203     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-6-ED     Document Type: Editorial

References (13)

1. Forman MR, Hursting SD, Umar A, Barrett JC. Nutrition and Cancer Prevention: A multidisciplinary perspective on human trials. Annu Rev Nutr 2004;24:223-54.
2. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000;342:1156-62.
3. Maskarinec G, Takata Y, Franke AA, Williams AE, Murphy SP. A 2-year soy intervention in premenopausal women does not change mammographic densities. J Nutr 2004;134:3089-94.
4. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
5. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
6. McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001;19:3938-43.
7. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
8. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
9. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790-804.
10. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
11. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. Engl J Med 2003;348:883-90.
12. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003 May;72:1117-30.
13. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339-47.